|
Tier 1 (Data demonstrating benefit- same tumor type, same gene)
|
|
14-85546
|
CML
|
BCR-ABL1
|
Fusion
|
TKI
|
|
13-45348a
|
AML
|
IDH1
|
c.394C > T (p.R132C)
|
IDH Inhibitor
|
|
14-24794a
|
AML
|
c-KIT; TET2; FLT3
|
c.2446G > C (p.D816H); c.3663delT (p.C1221Wfs); c.2505 T > G (p.D835E)
|
TKI; Hypomethylating agent; TKI
|
|
14-53198
|
AML
|
TET2
|
c.1156G > T (p.V386L)
|
Hypomethylating agent
|
|
13-77086
|
AML
|
c-KIT
|
c.1965 T > G (p.Asn655Lys)
|
TKIb
|
|
Tier 2 (Data demonstrating benefit- different tumor type, same gene)
|
|
15-18928
|
Hepatic rhabdoid tumor
|
SMARCA4
|
c.3574C > T (p.R1192C)
|
EZH2 Inhibitor
|
|
14-13487
|
Osteosarcoma
|
TSC1
|
c.2503-1G > C (p.?)
|
mTOR Inhibitor
|
|
14-47205
|
Nephroblastomatosis
|
PIK3CA
|
c.1035 T > A (p.N345K)
|
PI3K/AKT/mTOR Inhibitor
|
|
15-40141
|
Pleomorphic xanthoastrocytoma
|
TMEM106B-BRAF
|
Fusion
|
MEK Inhibitor
|
|
Tier 3 (Published, presented, in press pre-clinical data demonstrating benefit- same tumor type, same gene)
|
|
15-64793
|
ALL
|
FOXP1-ABL1
|
Fusion
|
TKIb
|
|
15-26188
|
ALL
|
NUP214-ABL1
|
Fusion
|
TKIb
|
|
15-79700
|
ALL
|
NRAS
|
c.183A > T (p.Q61H)
|
MEK Inhibitor
|
|
14-20062
|
ALL
|
KRAS
|
c.183A > T (p.Q61H)
|
MEK Inhibitor
|
|
14-24794a
|
AML
|
NRAS
|
c.183A > C (p.Q61H)
|
MEK Inhibitor
|
|
15-29224
|
AML
|
JAK3
|
c.1718C > T (p.A573V)
|
JAK Inhibitor
|
|
13-45348a
|
AML
|
NRAS
|
c.38G > C (p.G13A)
|
MEK Inhibitor
|
|
13-95124
|
AML
|
NRAS; MLL-AFF1 (KMT2A-AFF1)
|
c.182A > G (p.Q61R); Fusion
|
MEK Inhibitor; DOT1L Inhibitor
|
|
14-45760
|
AML
|
NRAS
|
c.38G > A (p.G13D)
|
MEK Inhibitor
|
|
13-50662
|
AML
|
PTPN11
|
c.1508G > T (p.G503V)
|
MEK Inhibitor
|
|
14-15491
|
AML
|
NUP98-NSD1
|
Fusion
|
DOT1L Inhibitor
|
|
14-27243
|
Neuroblastoma
|
NRAS
|
c.181C > A (p.Q61K)
|
MEK Inhibitor
|
|
14-70449
|
Rhabdomyosarcoma
|
NRAS
|
c.181C > A (p.Q61K)
|
MEK Inhibitor
|
|
14-42817
|
Neuroblastoma
|
KRAS
|
c.34G > T (p.G12C)
|
MEK Inhibitor
|
|
15-11925a
|
Osteosarcoma
|
MYC
|
Overexpression
|
BET Inhibitor
|
|
16-74654
|
Rhabdomyosarcoma
|
FGFR4
|
c.1582G > T (p.G528C); c.1648G > C (p.V550L)
|
FGFR4 Inhibitor
|
|
15-23518
|
Rhabdomyosarcoma
|
FGFR4
|
c.1648G > C (p.V550L); c.1949G > T (p.R650L); Overexpression
|
FGFR4 Inhibitor
|
|
14-37237
|
Glioblastoma multiforme
|
Gain 12q.14.1 involving CDK2
|
Copy number
|
CDK4/6 Inhibitor
|
|
15-44470
|
Medulloblastoma
|
PTCH1, SUFU, ZIC3
|
Overexpression
|
SMO Inhibitor
|
|
15-10838
|
Glioma
|
H3F3A; FGFR1
|
c.83A > T (p.K28M); c.1731C > A (p.N577K)
|
HDAC Inhibitor
|
|
15-27992
|
Hepatic rhabdoid tumor
|
Homozygous deletion of chr 22q11.23 with homozygous deletion of SMARCB1; Loss of expression of SMARCB1
|
Copy number; Loss of expression with biallelic deletion
|
EZH2 Inhibitor
|
|
Tier 4 (Published, presented, in press pre-clinical data demonstrating benefit- different tumor type, same gene)
|
|
15-36388
|
AML
|
MLL3 (KMT2C)
|
c.2110G > T (p.E704X)
|
BET Inhibitor
|
|
13-72282
|
T-ALL
|
KRAS; JAK1; STAT5B
|
c.40G > A (p.V14I); c.3076A > G (p.K1026E); c.2110A > C (p.I704L)
|
MEK Inhibitor; JAK Inhibitor; BCL2/BCLX-L Inhibitor
|
|
15-66870
|
Adrenocortical carcinoma
|
ALK
|
c.3436C > A (p.Q1146K)
|
ALK Inhibitorb
|
|
Tier 5 (Anything else the molecular tumor board thought was sufficient to qualify for treatment planning)
|
|
15-16072
|
ALL
|
SMARCC2-PDGFRB
|
Fusion
|
TKI
|
|
14-75899
|
Neuroblastoma
|
CDK4, MDM2
|
Overexpression
|
NEPENTHE trial [NCT02780128]
|
|
15-11925a
|
Osteosarcoma
|
MCL1, CCNE1
|
Overexpression
|
CDK4/6 Inhibitor
|
|
15-35162
|
Osteosarcoma
|
CUL4A
|
Overexpression
|
NAE Inhibitor
|
|
14-71727
|
Osteosarcoma
|
RAD51C
|
c.24 T > G (p.F8L)
|
PARP Inhibitor
|
|
15-83826
|
Osteosarcoma
|
PDGFRA, KDR (VEGFR2)
|
Overexpression
|
MTKIb
|
|
13-21968
|
Congenital fibrosarcoma
|
EML4-NTRK3
|
Fusion
|
ALK Inhibitor
|
|
14-84044
|
Inflammatory myofibroblastic tumor
|
VCAN-IL23R
|
Fusion
|
JAK Inhibitorb
|
